1. Campanati A, Marani A, Martina E, Diotallevi F, Radi G, Offidani A. Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines. 2021 Oct 21;9(11):1511. doi: 10.3390/biomedicines9111511. PMID: 34829740; PMCID: PMC8615182.
2. Nair PA, Badri T. Psoriasis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448194/
3. Gudjonsson JE, Elder JT. Psoriasis. Dalam: Kang S, editor. Fitzpatrick’s dermatology. Ninth edition. New York: McGraw-Hill Education; 2019.
4. Siswati AS, Rosita C, Triwahyudi D, Budianti WK, Mawardi P, Dwiyana RF, et al. Psoriasis. In: Pedoman Praktik Klinik (PPK) bagi Dokter Spesialis Dermatologi dan Venereologi Indonesia. PERDOSKI. 2021:294-308
5. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017 Mar;76(3):377-390. doi: 10.1016/j.jaad.2016.07.064. PMID: 28212759; PMCID: PMC5731650.
6. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, Gelfand JM. Psoriasis and comorbid diseases: Implications for management. J Am Acad Dermatol. 2017 Mar;76(3):393-403. doi: 10.1016/j.jaad.2016.07.065.PMID: 28212760;PMCID: PMC5839668.
7. Ronholt K, Iversen L. Old and New Biological Therapies for Psoriasis. Int J Mol Sci. 2017 Nov 1;18(11):2297. doi: 10.3390/ijms18112297. PMID: 29104241; PMCID: PMC5713267.
8. Monks G, Rivera-Oyola R, Lebwohl M. The Psoriasis Decision Tree. J Clin Aesthet Dermatol. 2021 Apr;14(4):14-22. Epub 2021 Apr 1. PMID: 34055182; PMCID: PMC8142826.
9. Wu J, Petto H, Dutronc Y, Burkhardt N, Gebauer K, Gooderham M. Development and validation of a new method for potential use of Psoriasis Area and Severity Index in teledermatology. Australas J Dermatol. 2021 Feb;62(1):e114-e117. doi: 10.1111/ajd.13412. Epub 2020 Aug 16. PMID: 33247832; PMCID: PMC7891613
10. Clinical Review Report: Ixekizumab (Taltz). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017. APPENDIX 6, Validity of Outcome Measures. https://www.ncbi.nlm.nih.gov/books/NBK533695/
11. Langenbruch A, Radtke M a., Gutknecht M, Augustin M. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol. 2019;33(1):123–7.
12. Golbari NM, Porter ML, Kimball AB. Current guidelines for psoriasis treatment: a work in progress. Cutis. 2018 Mar;101(3S):10–2.
13. Meneguin S, de Godoy N, Pollo C, Miot H, de Oliveira C. Quality of life of patients living with psoriasis: a qualitative study. BMC Dermatology. 2020;20(1).
14. Khan JM, Rathore MU, Tahir M, Abbasi T. Dermatology Life Quality Index In Patients Of Psoriasis And Its Correlation With Severity Of Disease. J Ayub Med Coll Abbottabad. 2020 Jan-Mar;32(1):64-67. PMID: 32468758.